The Asia-Pacific beta glucan market is expected to showcase a CAGR of 7.38% during the forecast period of 2019-2027. China dominated the beta glucan market in this region with a revenue of $xx million in 2018. The country is also expected to register the highest CAGR in the Asia-Pacific market over the forecast period.
The beta glucan market is segmented on the basis of end-users, category and sources. Apart from China, the other key markets in this region include India, Japan, Australia, South Korea and the Rest of APAC. High disposable income, growing prevalence of cancer and increasing demand from the bakery industry are expected to drive the need for the Asia-Pacific beta-glucan market.
Some of the noted market players in this market are Tate and Kyle PLC, Kerry Group PLC, Ceapro Inc., DSM NV, Super Beta Glucan Inc., Millipore Sigma, Kemin Industries, Biotech PharmaCon ASA, Lesaffre Human Care, Cargill Incorporated, Garuda International Inc., and Immunomedic AS.